Intravitreal Bevacizumab Injection for Eales Disease with Recurrent Vitreous Hemorrhage

Anar Toishubai¹, Baasankhuu Jamiyanjav², Uranchimeg Davaatseren², Bulgan Tuvaan², Burenjargal Peljee³

¹The Department of Ophthalmology, Shastin Central Hospital, Ulaanbaatar, Mongolia
²Health and Science Univercity of Mongolia, Ulaanbaatar, Mongolia
³The Department of Ophthalmology, Central Hospital, Ulaanbaatar, Mongolia

Purpose: To report the therapeutic effect of intravitreal injection bevacizumab for Eales disease with recurrent vitreous hemorrhage.

Methods: One young man was diagnosed Eales disease with recurrent vitreous hemorrhage. He had right eye blind and left eye visual acuity was hand motion. Left eye was treated with two intravitreal bevacizumab injections (Avastin®) at a three monthly interval.

Results: Patient's visual acuity was improve 0.8 after one month and dramatic regression of vitreous hemorrhage and no recurrent vitreous hemorrhage at 1 year of follow-up. No ocular or systemic side effects were observed.

Conclusion: Intravitreal injection of bevacizumab might be effective for Eales disease with recurrent vitreous hemorrhage.